Concepedia

John Mascarenhas

JM

Statistics

Publications

157

Citations

7.7K

H-Index

46

Active since

1996

Affiliations

Icahn School of Medicine at Mount Sinai(Current)

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

Tisch Hospital

Mayo Clinic in Arizona

John Mascarenhas is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, myeloproliferative neoplasms, and hematology.

ORCID

Publications per year

1996–2025

157

Publications

157

Complement-dependent Clearance of Apoptotic Cells by Human Macrophages

Dror Mevorach, John Mascarenhas, Debra Gershov et al. · The Journal of Experimental Medicine · 1998 · 692 citations · Full text

, , +17

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis

John Mascarenhas, Ronald Hoffman, Moshe Talpaz et al. · JAMA Oncology · 2018 · 380 citations · Full text

, , +13

Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells

Richard R. Furman, Zahra Asgary, John Mascarenhas et al. · The Journal of Immunology · 2000 · 274 citations

, , +17

Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis

John Mascarenhas, Ronald Hoffman · Clinical Cancer Research · 2012 · 243 citations

, , +15

Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey

Ruben A. Mesa, Carole B. Miller, Maureen Thyne et al. · BMC Cancer · 2016 · 191 citations · Full text

, , +15

1–5 of 157